The first and only clinically validated circulating TTMV® DNA blood test that aids in the detection of HPV-driven cancer.

Intervene earlier.

NavDx® is the first and only clinically validated circulating tumor-tissue-modified HPV (TTMV) DNA blood test that can aid in the detection of HPV-driven cancer.¹˒³

NavDx uncovers the presence of HPV+ cancer across the patient care continuum, so treating physicians can intervene earlier, which may result in improved outcomes.¹˒²˒³˒⁴ Use NavDx to optimize clinical management across the care continuum by:

Confirming the tumor HPV genotype²
Assessing current treatment response¹
Identifying molecular residual disease post-treatment¹
Detecting recurrences earlier than the current standard-of-care surveillance schedule.¹˒³˒⁴

The clinical utility of NavDx has been validated in a 3-year longitudinal study and demonstrated in real-world practice.¹˒³

This innovative and accessible blood test enables you to optimize HPV-driven cancer care and reassure patients that their disease is being effectively monitored.¹˒³

Detect recurrence before a PET or CT.

Uncover the presence of HPV+ head and neck cancer across the care continuum. NavDx® lets you optimize clinical management of HPV-driven cancer by accurately assessing treatment response, identifying the presence of post-treatment molecular residual disease, and conveniently monitoring for recurrence.¹˒³

Distinguish tumor-tissue-modified HPV (TTMV®) DNA from non-cancerous sources of HPV DNA.²
Verify the presence of molecular residual disease post-treatment, to identify and prioritize patients appropriate for adjuvant or follow-on chemoradiation treatment.¹
Safely surveil based on highly accurate positive (≥95%) and negative (≥95%) predictive values for active HPV-driven malignancy.¹˒³
Accurately detect recurrence a median of 4 months earlier than it would present clinically via PET or CT scan to facilitate earlier initiation of salvage therapy.¹

NavDx enables physicians to optimize HPV-driven cancer care and reassure patients that their disease is being effectively monitored.¹˒³

Optimize HPV+ cancer care with NavDx to:

CONFIRM

the tumor HPV genotype.²

ASSESS

treatment response.¹

IDENTIFY

the presence of post-treatment molecular residual disease, and accurately.¹˒³

DETECT

recurrence significantly earlier than it would present clinically.¹˒²˒³˒⁴

Reliable and easy reporting.

The easy-to-interpret, actionable test report helps inform clinical decisions, enabling physicians to intervene earlier, which may result in improved outcomes.¹˒³

>95% sensitivity for recurrence detection, as validated in a 3-year prospective clinical study.¹
>99% probability of being recurrence-free as long as TTMV HPV DNA remains undetectable after treatment.¹
Detects recurrences earlier than the current standard-of-care surveillance schedule.¹˒³˒⁴
Reports are issued within 7 calendar days from sample receipt by the Naveris lab.